ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026

▤ Summary

ITM announced new Phase 3 COMPETE data at SNMMI 2026 showing that single-timepoint dosimetry may deliver accurate individualized dose estimates for radiopharmaceutical therapy. The analysis used imaging data from patients treated with 177Lu-edotreotide and compared a population-based modeling approach against established single-timepoint methods. The results suggest clinics may need fewer imaging sessions to support personalized dosimetry, which can reduce workflow burden and patient inconvenience. ITM positions the findings as a step toward broader routine use of precision radiopharmaceutical therapy in clinical settings.

▦ Linked Companies